Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a kind of EGFR/HER2 receptor tyrosine kinase inhibitor in the preparation of medicine for treating cancer

A technology of use and medicine, applied in the field of use of EGFR/HER2 receptor tyrosine kinase inhibitors in the preparation of medicines for treating cancer, capable of solving the problem of antibody medicines that do not disclose the cancer use of the compound of formula I and do not disclose the anti-HER2 effect Issues such as the combined use of conjugates

Active Publication Date: 2022-05-27
JIANGSU HENGRUI MEDICINE CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] However, none of the above documents discloses the use of the compound of formula I for the treatment of cancers that have failed or resistant to anti-HER2 treatment, nor discloses the combined use of the compound of formula (I) and the antibody-drug conjugate with anti-HER2 effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a kind of EGFR/HER2 receptor tyrosine kinase inhibitor in the preparation of medicine for treating cancer
  • Application of a kind of EGFR/HER2 receptor tyrosine kinase inhibitor in the preparation of medicine for treating cancer
  • Application of a kind of EGFR/HER2 receptor tyrosine kinase inhibitor in the preparation of medicine for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Efficacy of compound (I), T-DM1 alone, or a combination of both on Herceptin-resistant breast cancer BT-474 / T721 naked mouse subcutaneous transplant tumor

[0028] 1. The drug under test

[0029] Drug name and batch number: Compound (I) is a yellow powder with a content of 98.8%, batch number S0915100514; T-DM1, a white lyophilized powder, specification 80mg / bottle, batch number P07A113010711.

[0030] Drug source: Compound (I) is administered in its dimalate form, prepared in accordance with the method disclosed in CN102933574B; T-DM1 is prepared according to the method disclosed in CN101087611A.

[0031] Preparation method: Compound (I) is prepared with distilled water; T-DM1 is first re-dissolved with distilled water into a 20mg / ml solution, aliquoted at -80 degrees, and diluted with 0.1% BSA normal saline to the corresponding concentration before use.

[0032] 2. Laboratory animals

[0033] BALB / cA-nude nude mice, 6-7 weeks, ♀ purchased from Shanghai Lingch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of medicines for treating cancer. Specifically, the present invention relates to the use of a compound represented by the EGFR / HER2 receptor tyrosine kinase inhibitor formula (I) in the preparation of a drug for treating anti-HER2 drug-resistant cancer.

Description

Technical field [0001] The present invention relates to the use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of a drug for the treatment of anti-HER2 therapy for drug-resistant cancer. Background [0002] Breast cancer is one of the most common malignancies in women. According to the World Health Organization, about 1.2 million women worldwide are diagnosed with breast cancer each year, and the incidence of breast cancer rises at a rate of 5% to 20% each year. [0003] Its incidence is often genetically related, and the incidence is higher in women between the ages of 40 and 60 and around menopause. Only about 1 to 2% of breast patients are male. Malignant tumors usually occur in the epithelial tissue of the breast glands. It is one of the most common malignant tumors that seriously affects women's physical and mental health and even endangers their lives. [0004] There are many factors known to induce this disease, mainly the following factors: (1) Ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4709A61K45/06A61K39/395A61P35/00
Inventor 杨昌永曹国庆唐蜜孙星孙扬飞张连山
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com